Sanofi wants to assess the potential of DNL747 in neurological diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), ... read more
Sanofi and Denali Therapeutics ink €1.125bn deal in neurology/inflammation
Sanofi and Denali Therapeutics ink €1.125bn deal in neurology/inflammation
